DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis Post ContentdrrxRead More You might also be interested in reading CleanSpark ups mined BTC while selling into strength. March 27, 2025 In Mainstream ← Previous post Next post →